Journal of Science and Medicine in Sport
Volume 14, Issue 1 , Pages 58-64 , January 2011

Variation in the PPARα gene in Polish rowers

  • Agnieszka Maciejewska

      Affiliations

    • Department of Genetics, University of Szczecin, Poland
    • Corresponding Author InformationCorresponding author.
    • ,
  • Marek Sawczuk

      Affiliations

    • Department of Genetics, University of Szczecin, Poland
    • ,
  • Paweł Cięszczyk

      Affiliations

    • Institute of Physical Culture, University of Szczecin, Poland

Received 19 November 2009 ,Revised 11 May 2010 ,Accepted 31 May 2010.

References 

  1. Ostrander EA, Huson HJ, Ostrander GK. Genetics of athletic performance. Annu Rev Genom Humen Genet. 2009;10:407–429
  2. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999;20(5):649–688
  3. van Raalte DH, Li M, Pritchard PH, et al. Peroxisome proliferator-activated receptor (PPAR)-α: a pharmacological target with a promising future. Pharm Res. 2004;21(9):1531–1538
  4. Steineger HH, Sørensen HN, Tugwood J, et al. Dexamethasone and insulin demonstrate marked and opposite regulation of steady-state mRNA level of the peroxisomal proliferator-activated receptor (PPAR) in hepatic cells. Eur J Biochem. 1994;225:967–974
  5. Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry. 1993;32(21):5598–5604
  6. Juge-Aubry CE, Hammar E, Siegrist-Kaiser C, et al. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor α by phosphorylation of a ligand-independent trans-activating domain. J Biol Chem. 1999;274:10505–10510
  7. Flavell DM, Pineda Torra I, Jamshidi Y, et al. Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects. Diabetologia. 2000;43:673–680
  8. Flavell DM, Jamshidi Y, Hawe E, et al. Peroxisome proliferator-activated receptor α gene variants influence progression of coronary atheroscelorsis and risk of coronary artery disease. Circulation. 2002;105(12):1440–1445
  9. Andrulionyte L, Kuulasmaa T, Chiasson J-L, et al. Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-α gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes. Diabetes. 2007;56:1181–1186
  10. Jamshidi Y, Montgomery HE, Hense H-W, et al. Peroxisome proliferator-activated receptor α gene regulates left ventricular growth in response to exercise and hypertension. Circulation. 2002;105:950–955
  11. Sack MN, Rader TA, Park S, et al. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation. 1996;94:2837–2842
  12. Ahmetov II, Mozhayskaya IA, Flavell DM, et al. PPARα gene variation and physical performance in Russian athletes. Eur J Appl Physiol. 2006;97:103–108
  13. Druzhevskaya AM, Ahmetov II, Astratenkova IV, et al. Association of the ACTN3 R577X polymorphism with power athlete status in Russians. Eur J Appl Physiol. 2008;103:631–634
  14. Eynon N, Meckel Y, Sagiv M, et al. Do PPARGC1A and PPARα polymorphisms influence sprint or endurance phenotypes?. Scand J Med Sci Sports. 2009;
  15. Chen ES, Mazzotti DR, Furuya TK, et al. Association of PPARα gene polymorphisms and lipid serum levels in a Brazilian elderly population. Exp Mol Pathol. 2010;88:197–201
  16. Ahmetov II, Williams AG, Popov DV, et al. The combined impact of metabolic gene polymorphisms on elite endurance athlete status and related phenotypes. Hum Genet. 2009;
  17. Campos H, Genest JJ, Blijlevens E, et al. Low lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992;12(2):187–195
  18. Lemieux I, Laperriere L, Dzavik V, et al. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis. 2002;162:363–371
  19. Vu-Dac N, Chopin-Delannoy S, Gervois P, et al. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem. 1998;273:25713–25720
  20. Tu AY, Albers JJ. Glucose regulates the transcription of human genes relevant to HDL metabolism: responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes. 2001;50(8):1851–1856
  21. Balcerzyk A, Zak I, Krauze J. Synergistic effect between polymorphisms of PPARA and ABCA1 genes on the premature coronary artery disease. Acta Cardiol. 2007;62(3):233–238
  22. Lawn RM, Wade DP, Garvin MR, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest. 1999;104:R25–R31
  23. Cresci S, Jones PG, Sucharov CC, et al. Interaction between PPARA genotype and β-blocker treatment influences clinical outcomes following acute coronary syndromes. Pharmacogenomics. 2008;9(10):1403–1417
  24. Doney ASF, Fisher B, Lee S, et al. Association of common variation in the PPARA gene with incident myocardial infraction in individuals with type 2 diabetes: a Go-DARTS study. Nucl Recept. 2005;3:4
  25. Kim H, Haluzik M, Asghar Z, et al. Peroxisome proliferator-activated receptor-α agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes. 2003;52:1770–1778
  26. Tenenbaum A, Motro M, Fisman EZ, et al. Peroxisome proliferatoractivated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004;109:2197–2202
  27. Flavell DM, Ireland H, Stephens JW, et al. Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes. Diabetes. 2005;54(2):582–586
  28. Horowitz JF, Leone TC, Feng W, et al. Effect of endurance training on lipid metabolism in women: a potential role for PPARα in the metabolic response to training. Am J Physiol Endocrinol Metab. 2000;279:348–355
  29. Russell AP, Feilchenfeldt J, Schreiber S, et al. Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-γ coactivator-1 and peroxisome proliferator-activated receptor-α in skeletal muscle. Diabetes. 2003;52:2874–2881
  30. Kramer DK, Ahlsen M, Norrbom J, et al. Human skeletal muscle fibre type variations correlate with PPARα, PPARδ and PGC-1α mRNA. Acta Physiol. 2006;188:207–216
  31. Foucher C, Rattier S, Flavell DM, et al. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics. 2004;14(12):823–829

PII: S1440-2440(10)00121-0

doi: 10.1016/j.jsams.2010.05.006

Journal of Science and Medicine in Sport
Volume 14, Issue 1 , Pages 58-64 , January 2011

Article Tools

* Image Usage & Resolution